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Abstract: Candidemia cases have been increasing, especially among immunosuppressed patients.
Candida glabrata is one of the most resistant Candida species, especially to the azole drugs, resulting in
a high demand for therapeutic alternatives. The minimum inhibitory concentration (MIC), minimum
fungicidal concentration (MFC), and minimum biofilm eradication concentration (MBEC) were
determined for posaconazole (Pcz) and amphotericin B (AmB). The drug combinations of both
drugs were evaluated on pre-formed biofilms of C. glabrata ATCC 2001, through XTT (2,3-bis
(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay, colony forming units
(CFU), crystal violet, and the fractional inhibitory concentration index (FICI). C. glabrata revealed
higher susceptibility and biofilm reduction in the presence of AmB alone, but both drugs revealed a
good capacity in the biomass elimination. In the majority of the tested combinations, the interactions
were defined as indifferent (FICI ≤ 4). The combination of the two drugs does not seem to bring a
clear advantage in the treatment of biofilms of C. glabrata.
Keywords: Candida; posaconazole; amphotericin B; biofilms; matrix; antifungal drug; antifungal
combination; resistance; Candida glabrata
1. Introduction
Systemic fungal infections caused by Candida species have increased in the last decade, in parallel
with the number of immunocompromised patients [1,2]. Candida glabrata is currently the second
most common cause of candidemia in the United States and the third in Europe [3,4]. Despite not
having the capacity to form filaments or to secrete proteases, C. glabrata has important virulence
factors, such as secretion of phospholipases, lipases, and hemolysins, and especially their ability to
form biofilms [1,5]. Biofilms are surface-associated communities of microorganisms embedded in
an extracellular matrix which confers protection and consequently a major resistance to antifungal
therapy [6–8]. The formation of Candida species biofilms raises significant clinical issues because of an
additional increase in antifungal drug resistance, as well as increased evasion of host immune defenses.
Furthermore, biofilm development on medical devices can cause the failure of the device and may
turn into a source of future infection [9].
This increase in C. glabrata infections is related to an inherent low susceptibility to azoles [10,11],
and can also be a result of rare mutations that are selected by drug pressure [12]. Accordingly, the cases
of fluconazole-refractory disease (resistance to fluconazole) associated with C. glabrata are common in
candidiasis. Therefore, the treatment of these infections relies on other azoles (e.g., voriconazole and
posaconazole-Pcz) or other classes of antifungal agents, such as polyenes (e.g., amphotericin B-AmB)
Microorganisms 2018, 6, 123; doi:10.3390/microorganisms6040123 www.mdpi.com/journal/microorganisms
Microorganisms 2018, 6, 123 2 of 11
and echinocandins [2,13]. However, resistance to polyenes has been reported on C. glabrata [14–18],
as well as resistance or low susceptibility to Pcz [19–21].
Pcz is a lipophilic broad-spectrum triazole drug introduced in 2007 [22,23], and the most recent
guidelines for the treatment of fungal infections indicate Pcz as a valuable choice in the therapy of
Candida intravascular infections, oropharyngeal or esophageal candidiasis [2,24]. Therapeutically,
Pcz offers advantages over fluconazole and voriconazole, since its activity seems to be less affected
by either mutation in ERG11 (ergosterol gene) or the overexpression of specific efflux pumps [25].
Overall, these data would indicate a beneficial effect of Pcz in clinical circumstances in which other
triazoles failed.
AmB is a polyene produced by Streptomyces nodosus [26,27], characterized by a macrocyclic ring
lactone, that has demonstrated to be effective for the treatment of candidemia in nonneutropenic
patients and urinary tract infections, especially due to C. glabrata and C. krusei [2]. Therefore, the main
aim of this research was to evaluate the in vitro activity of the combination of one azole (Pcz) and one
polyene (AmB) against C. glabrata mature biofilms.
2. Materials and Methods
2.1. Organism and Growth Conditions
The reference strain from the American Type Culture Collection, C. glabrata ATCC 2001, was used
in this study. For each experiment, C. glabrata ATCC 2001 was subcultured on Sabouraud dextrose
agar (SDA) (Merck, Darmstadt, Germany), for 24 h at 37 ◦C. Cells were then inoculated in Sabouraud
dextrose broth (SDB) (Merck, Darmstadt, Germany), and incubated for 18 h at 37 ◦C under agitation
at 120 rpm. After incubation, the cells were harvested by centrifugation at 3000 g for 10 min at 4 ◦C,
and washed twice with Phosphate Buffered Saline (PBS, pH = 7.5). Pellets were then suspended in
RPMI-1640 (Sigma-Aldrich, St. Louis, MI, USA), and the cellular density was adjusted to 1 × 105
cells/mL, using a Neubauer counting chamber [28].
2.2. Antifungal Drugs
Posaconazole was kindly provided by Merck®, in its pure compound. Amphotericin B was
purchased in Sigma® (Sigma-Aldrich, purity ~80%). Aliquots of 5000 mg/L were prepared using
dimethyl-sulfoxide (DMSO) for both drugs, and the final concentrations were prepared in RPMI-1640.
All susceptibility tests were performed according to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines [29,30].
2.3. Minimum Inhibitory Concentrations (MICs)
The tested concentrations of Pcz and AmB were prepared in RPMI-1640 (pH = 7). The inoculum
was prepared by suspending five distinct colonies, ≥1 mm diameter from 24 h cultures, in at least 3 mL
of sterile distilled water. The inoculum was then suspended by vigorous shaking on a vortex mixer
for 15 s, the cell density was adjusted to the density of a 0.5 McFarland standard, and adding sterile
distilled water as required, giving a yeast suspension of 1–5 × 106 colony forming units (CFUs)/mL.
A working suspension was prepared by a dilution of the standardised suspension in sterile distilled
water to yield 1–5 × 105 CFU/mL. The 96-well-plate was prepared with 100 µL of cell suspension and
100 µL of both antifungal agents (0.2 to 1 mg/L for Pcz, and 0.25 to 2 for AmB—2 × concentrated)
and incubated at 37 ◦C during 18–48 h. Positive controls without Pcz and AmB were also performed.
According to the EUCAST, the MIC was determined as the lowest concentration (recorded in mg/L)
of the drug that inhibits the growth of the yeasts to a predefined degree: 90% in the case of AmB
(polyenes) and 50% for posaconazole (azoles) [29,30]. The results were visualized by spectrometry at
530 nm [29,30].
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2.4. Minimum Fungicidal Concentration (MFC)
In addition to the previous step, 20 µL of each cell suspension treated with Pcz and AmB was
recovered to a new well, and serial decimal dilutions in PBS were plated onto SDA. Agar plates were
incubated for 24 h at 37 ◦C and the total number of CFUs were determined. The results were presented
as Log10 CFU per area (Log10 CFUs/cm2) [28–30].
2.5. Minimum Biofilm Eradication Concentration (MBEC)
Standardized cell suspensions (1 × 105 cells/mL) were placed into selected wells of 96-wells
polystyrene microtiter plates (200 µL) (Orange Scientific, Braine-l‘Alleud, Belgium). RPMI-1640
was used without cells, but with an antifungal agent as a negative control. As positive control,
cell suspensions were tested without an antifungal agent. At 24 h, 100 µL of RPMI 1640 was removed
and an equal volume of fresh RPMI 1640 plus the antifungal concentration were added (Pcz: 200;
300 and 600 mg/L; AmB: 0.5; 1; 2; and 4 mg/L, 2 × concentrated). The plates were incubated at 37 ◦C
for an additional 24 h at 120 rpm. The number of cultivable cells on biofilms was determined by the
enumeration of CFUs. To achieve this, the mediums were aspirated, and biofilms were washed once
with 200 µL of PBS to remove non-adherent cells. Then, biofilms were scraped from the wells and the
suspensions were vigorously vortexed for 2 min to disaggregate cells from the matrix. Serial decimal
dilutions in PBS were plated on SDA and incubated for 24 h at 37 ◦C. The results were presented as
Log10 CFU per area (Log10 CFUs/cm2) [13,29,30].
2.6. XTT Reduction and Checkerboard Assay
Biofilms were formed as explained previously. The metabolic activity of the biofilms was measured
by assaying 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction,
a reaction catalyzed by mitochondrial dehydrogenases, as described before [31]. Briefly, biofilms were
washed with sterile ultrapure water and were then incubated with 100 µg/mL XTT and 10 µg/mL
PMS at 37 ◦C for 3 h at 120 rpm. Following this, the optical density (OD) was measured at 490 nm
using a microtitre plate reader. The metabolic activity of each drug combination was compared with
that of the drug-free biofilms and drug-alone biofilms (control biofilms).
2.7. Interpretation of Drug Combination Interaction
Drug combination (200 mg/L of Pcz and 0.5 mg/L of AmB) interaction was classified by the
fractional inhibitory concentration index (FICI) [32,33]. The FICI was calculated by the formula:
FICI = (Ac/Aa) + (Bc/Ba), where Ac and Bc are the metabolic activity of the biofilm cells with antifungal
drugs in combination, and Aa and Ba are the metabolic activity of the biofilm cells with antifungal
drugs A and B alone. The interaction was defined as synergistic if the FICI was ≤0.5, additive if FICI
was >0.5 and ≤1, indifferent if the FICI was >1 and ≤4, and antagonistic if the FICI was >4.0.
2.8. Biofilm Total Biomass Quantification—Crystal Violet Staining
Total biofilm biomass was quantified by Crystal Violet (CV) staining [28]. After biofilm formation,
the medium was aspirated, and non-adherent cells removed by washing the biofilms with sterile
ultra-pure water. Then, biofilms were fixed with 200 µL methanol, which was removed after 15 min of
contact. The microtiter plates were allowed to dry at room temperature, and 200 µL of CV (1% v/v)
was added to each well and incubated for 5 min. The wells were then gently washed twice with sterile,
ultra-pure water and 200 µL of acetic acid (33% v/v) was added to release and dissolve the stain.
The absorbance of the obtained solution was read in triplicate in a microtiter plate reader (Bio-Tek
Synergy HT, Izasa, Lisbon, Portugal) at 570 nm. The results were presented as absorbance per unit
area (Abs/cm2).
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2.9. Statistical Analysis
Experiments were repeated three times in independent assays. Results were compared using
one-way analysis of variance (ANOVA) and Dunnett’s multiple comparisons tests, using GraphPad
Prism 7 software. All tests were performed with a confidence level of 95%.
3. Results and Discussion
Systemic candidiasis is a growing problem worldwide, especially in critically
immunocompromised patients [1,34]. This disease is associated with severe rates of morbidity,
mortality, and high economic costs [34,35], hence the choice of the most appropriate therapy is crucial
to achieve a clinical cure.
Therefore, the two drugs studied in this work were selected since both are used in the treatment
of candidemia and have different mechanisms of action [2].
Table 1 shows the results of the determinations of MIC, MFC, and MBECs for Pcz and AmB for C.
glabrata ATCC 2001.
Table 1. MICs, MFCs and MBECs determined for posaconazole and amphotericin B for C. glabrata
ATCC 2001.
Drug MIC (mg/L) MFC (mg/L) MBEC (mg/L)
Posaconazole 0.7 0.8–0.9 >300
Amphotericin B 0.25 1–2 2–4
MIC: minimum inhibitory concentration; MFC: minimum fungicidal concentration; MBEC: minimum biofilm
eradication concentration.
Although the 2017 EUCAST guidelines do not specify an epidemiological cut-off value (ECOFFs)
for C. glabrata strains regarding Pcz, it is indicated that, for this species, these values are in general
higher than for C. albicans (sensible ≤ 0.064 mg/L; resistant > 0.064 mg/L). Pfaller et al. [36] and
Spregnini et al. [37] suggested similar results: 0.5–1 mg/L and ≤0.03 to 0.5 mg/L, respectively.
Thus, the value observed (0.7 mg/L) seems to indicate a tolerant profile [30]. Regarding the AmB
MICs, EUCAST points out that strains with values of AmB ≤ 1 mg/L should be considered sensible,
which was the case, since the MIC value was 0.25 mg/L (Table 1) [30]. Surprisingly, MIC and MFC
determinations for Pcz showed that this drug has a good activity in planktonic cells. Comparing the
MIC and the MFC values, they are approximately the same (0.8–0.9 mg/L vs. 0.7 mg/L). In recent
works published by our group, the MFC for fluconazole (Flu) and voriconazole (Vcz) for C. glabrata
ATCC 2001 was almost 200 times and four times higher than the MIC, respectively [28,38]. Thus,
the result for Pcz shows an enhanced effectiveness to eliminate planktonic cells, in comparison to
Flu and Vcz [28]. Furthermore, the comparable MICs determined for Pcz and Vcz (0.7 and 0.5 mg/L,
respectively) confirm the parallel Pcz in vitro activity against Candida species that have been reported
for both drugs [39].
Figure 1 shows the effect of Pcz (Figure 1A,C) and AmB (Figure 1B,D) on C. glabrata ATCC 2001
biofilm cells and biomass. Regarding analysis of biofilm cells (enumeration of CFU), Pcz was found to
reduce 1 Log10 CFU/cm2 of the C. glabrata ATCC 2001 biofilm cells, when using 200 mg/L (p < 0.0005).
Curiously, there was no observed improvement in biofilm cells reduction when increasing the dose
(Figure 1A). On the other side, AmB displayed a better performance, reducing 2 Log10 CFU/cm2
from 2 mg/L (Figure 1C). Concerning the biomass decrease, both drugs revealed to be good biofilm
reducers. Pcz revealed a statistically significant higher biomass drop with the lower concentration
(77.6%, p < 0.0001), in comparison with 2 mg/L of AmB (64.2%, p < 0.0001) (Figure 1C,D).
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of the biomass is presented by abs/cm2. (* p < 0.05; ** p < 0.001; *** p < 0.0005; **** p < 0.0001). 
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AmB, clinical concentrations were applied in mature biofilms of C. glabrata ATCC 2001. It is important 
to note that the concentrations used were the MICs of Pcz and AmB, and doses similar to the protocols 
used in invasive candidiasis [2]. 
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Figure 1. Effect of posaconazole (A) and amphotericin B (B) on C. glabrata ATCC 2001 biofilms.
Mean values of the logarithm of colony forming units are normalized by unit of area (Log10 CFU/cm2).
Crystal Violet in a 48-hour-biofilm of C. glabrata ATCC 2001 are shown with and without posaconazole
(C) (200; 300; 600 mg/L) and amphotericin B (D) (0.25; 0.5; 1 mg/L). The quantification of the biomass
is presented by abs/cm2. (* p < 0.05; ** p < 0.001; *** p < 0.0005; **** p < 0.0001).
Azol s as Pcz target the ergosterol biosynthetic pathway, specifically the 14-α sterol demethylases,
which are encoded by the ERG11 gene. Thus, these drugs are responsible for blocking the capacity
to build and renew sterols in the cellular mem ranes, changing membrane fluidity and function of
vital proces such as signaling, transport, exocytosis, and endocytosis [1,5]. Polyenes as AmB bind
to the ergoster l of the fungal cell wal , establishing t ans embrane aggregates, po es, and causing
membra e depo arization and membrane permeability, whi h leads to osmotic imbalance and fi ally
cell death [40–42].
Although not considered a first-line drug for primary candidiasis therapy, Pcz is used in ca es of
Candid infections as a st pping-down therapy for isolates that are susceptible to those agents but not
susceptible to Flu (fluconazole-refractory isease) [2]. The concomitant use of azoles and polyenes
has been evalua ed in ome reports in other species [2,43–48]. With the purpose f evaluati g the
a tifungal effect (synergism, additive, indifferent, or antagonism) of the combination of Pcz and AmB,
clinical concentrations were applied in matu e biofilms of C. glabra a ATCC 2001. It is important to
note that the concentration use were the MICs of Pcz d AmB, and dos s si ilar to the protocols
used in invasive candidiasis [2].
Figure 2A displays the check rboa d of the combinatory effect of different concen rations f Pcz
and AmB. The alues presented are determinations of the metabolic activity of the biofilms, obtained
through the XTT a say. These r sults corroborate CFU counts, since generally, AmB alone showed to
have a higher cap city to decrease the metabolic activity of the biofilm cells than Pcz al ne (Figure 2A).
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Further, in terms of metabolic activity, only one combination was able to achieve a 1% improvement
than using AmB alone (0.7 mg/L Pcz + 4 mg/L AmB).
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Figure 2. Checkerboard of the combinatory effect of different concentrations of Pcz and AmB.
The values are related to the metabolic activity of the biofilms, determined through the XTT assay (A)
(Bold: metabolic activity below 20%). Calculated FICI range of checkerboard experiments for C. glabrata
ATCC 2001 (B).
The determination of the FICI [32,33] values (Figure 2B), showed that the interaction of these
drug combinations was, in the majority of the cases, indifferent (>1 FICI ≥ 4), further endorsing
the obtained results. Moreover, none of the tested combinations demonstrated a synergistic effect
(FICI ≤ 0.5), nor an antagonistic one (FICI > 4), and only two combinations showed a slight additive
effect (>0.5 FICI ≤ 1): 0.7 mg/L Pcz + 2 mg/L AmB (FICI = 1.07—Additive/Indifferent) and 200 mg/L
Pcz + 0.5 mg/L AmB (FICI = 0.98—Additive). In order to verify the biofilm cell and the biomass
eliminations, CFU counts and crystal violet were performed for the combination with the better FICI
additive effect (200 mg/L Pcz + 0.5 mg/L AmB) (Figure 3). It was noted that in both combinations,
one of the antifungals had to be equal or very near the to the MBEC value to have an additive effect.
This fact does not appear to be clinically helpful, since it would also be interesting to reduce the high
concentrations needed to eradicate the biofilm, when using two drugs, in order to decrease possible
side effects [2].
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Figure 3. Effect of the combination of posaconazole and amphotericin B (200 + 0.5 mg/L) on C. glabrata
ATCC 2001 biofilms. Mean values of the logarithm of colony forming units normalized by unit of
area (Log10 CFU/cm2) (A). Crystal Violet in a 48-hour-biofilm of C. glabrata ATCC 2001, with and
without combination of posaconazole and amphotericin B (200 + 0.5 mg/L) (B). The quantification of
the biomass is presented by abs/cm2. (**** p < 0.0001).
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It was expected that in applying this specific combination, the reduction on biofilm cells were
at least 2 Log10 CFU/cm2 and also that the biofilm biomass would diminish. Nevertheless, none of
the objectives were properly achieved. The combination permitted a reduction of 2 Log10 CFU/cm2
(p < 0.0001), which was a better result than the use of Pcz alone, but did not show any clear advantages
than the single use of 4 mg/L of AmB, since, in this case, the Log10 CFU/cm2 reduction was higher
(2 in combination vs 2.9 AmB alone in the higher concentration applied). In fact, regarding the results
of the CFU counts and comparing both drugs individually, Pcz did not reveal a pronounced effect on
the eradication of biofilm cells (i.e.,≥2 Log10 CFU/cm2), applying the minimum or even the maximum
dose (Figure 1A).
On the other side, the good performance of the AmB alone (Figure 1B) demonstrated that,
even though cases of tolerance and resistance have been appearing [14,15,49], AmB is still among
the most effective drugs for the treatment of Candida infections. Other reports have stated similar
results in other Candida species [50–52]. Considering the biomass reduction, similar results were
obtained. The concomitant use of Pcz/AmB led to a good biomass reduction (69.3%), which is an
important feature of an antifungal drug in a treatment of an infection caused by biofilms. Yet, a higher
reduction was observed when Pcz was used alone (77.6%), but lower than when AmB was used
isolated (55.2% for 0.5 mg/L, data not shown) (Figures 1C,D and 2). It is documented that the biofilm
structure creates an exceptionally resistant profile to the antifungal drugs [1]. Together, these results
validate reports that the biofilm cells are much more resistant than the planktonic and are particularly
resistant to azoles (as Pcz), which has also been verified by other authors [16,51–58].
In line with our outcomes, Cacciapuoti and colleagues tested several combinations of AmB/Pcz
in different C. albicans strains. The results revealed cases of synergy but also cases of indifference [43].
Rex and colleagues showed comparable results with AmB and Flu [44]. The authors demonstrated
that the combination of AmB/Flu was as effective as higher-dose Flu given alone for patients with
candidemia [44]. In opposition, using other drug combinations (AmB, flucytosine, Pcz, caspofungin,
or FK506), the authors also reported in vitro synergism [2,45]. Additionally, no antagonism was detected
in Flu/AmB, saperconazole/AmB, or SCH39304(another azole)/AmB combination in candidiasis
studies in murine models [46–48,59]. One important feature is that none of these studies were
developed with biofilm cells, as the present study has done.
As the azoles block the ergosterol production which is the target of polyenes, this can reduce the
antifungal capacity of the latter (by decreasing the target concentration), which was also described in a
number of reports [60–62]. Indeed, one of the most important mechanisms of antifungal resistance is
the modulated expression of drug targets, as the membrane sterol composition of biofilms’ cells. It is
documented that cells from mature biofilms contain a significantly lower concentration of ergosterol,
especially during the later phases of biofilm growth, compared to the planktonic cells [63–69].
Additionally, the azole resistance profile of biofilms of C. glabrata and the interference of the antifungals
mechanisms of action explained above, may be reasons for the less expressive results in this Pcz/AmB
combination, compared with the use of the drugs alone. For this reason, and although there was no
clinical isolates evaluation in this report, it is expected that the present results can be extended to
them, as these drugs have a different mechanism of action but are both linked to ergosterol and the
cellular membrane.
As a final remark, combinational drug therapies have appeared due to the increase of cases of
antifungal drug resistance and are usually employed to treat patients with several immunosuppressing
diseases (e.g., HIV, cancer). These approaches are an important source of new therapeutic responses
and seem to have great potential in fungal infections therapy, but require a careful and constant
evaluation of the efficacy of the proposed schemes, before application in clinical practice.
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